TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07708727: An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

Sponsor: Gilead Sciences · Phase: PHASE2/PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 700 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$4,160,688

Rescue Site Savings

+$2,761,836

Unlock Full NCT07708727 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07708727 Rescue Dossier →